A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Verastem, Inc.
Servier
Pfizer
Pheon Therapeutics
Eli Lilly and Company
Teclison Ltd.
M.D. Anderson Cancer Center
Kestrel Therapeutics, Inc.
Boehringer Ingelheim
Zymeworks BC Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Montefiore Medical Center
Montefiore Medical Center
Nammi Therapeutics Inc
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
National Cancer Institute (NCI)
Bristol-Myers Squibb
Pfizer
Fred Hutchinson Cancer Center
Revolution Medicines, Inc.
Memorial Sloan Kettering Cancer Center
Cancer Research UK
Turning Point Therapeutics, Inc.
Actuate Therapeutics Inc.
Conjupro Biotherapeutics, Inc.
Alterome Therapeutics, Inc.
Abramson Cancer Center at Penn Medicine
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
City of Hope Medical Center
National Cancer Institute (NCI)
SystImmune Inc.
Pfizer
Institut Paoli-Calmettes
Brigham and Women's Hospital
RasCal Therapeutics, Inc.
Novartis
Frontier Medicines Corporation
Filamon LTD
Pfizer
PMV Pharmaceuticals, Inc
Mayo Clinic
Indiana University
Washington University School of Medicine
Tomsk National Research Medical Center of the Russian Academy of Sciences
Xencor, Inc.
Abramson Cancer Center at Penn Medicine
M.D. Anderson Cancer Center